REG - hVIVO PLC - Appointment of Non-Executive Chair

hVIVOAnnouncement

01/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250901:nRSA3425Xa&default-theme=true

RNS Number : 3425X  hVIVO PLC  01 September 2025

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Appointment of Non-Executive Chair

 

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and
the world leader in human challenge clinical trials, confirms that, further to
its announcement on 29 July 2025, Shaun Chilton has today joined the Board of
Directors as Non-Executive Chair with immediate effect.

 

Shaun brings substantial sector-relevant experience and expertise to the
Board, underpinned by a track record of delivering strong growth in sales and
enterprise value. He brings over 30 years of experience leading and managing
both private and public businesses. Shaun was previously Chief Executive
Officer of Clinigen Group plc, a global pharmaceutical services group
operating in more than 100 countries and has considerable board experience
within UK public companies. He is currently Non-Executive Chair of Avacta
Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory
Board Member of Product Life Group.

 

Elaine Sullivan, Interim Chair & Senior Non-Executive Director of hVIVO
plc, said: "We are delighted to welcome Shaun to the Board of hVIVO. Shaun
brings a wealth of sector-relevant experience and we believe his expertise
will support us as we continue to grow and diversify the Group. As a Board we
look forward to working closely with Shaun to help deliver on the Company's
mission and execute on our strategy."

 

Shaun Chilton, incoming Non-Executive Chair of hVIVO plc, said: "I am pleased
to join the Board of hVIVO plc, a Company which I believe has excellent
prospects as it continues to diversify its service offering while leading the
global charge in delivering exceptional human challenge trial services to its
clients."

 

Additional Information on the Board Appointment

 

The following additional information is provided with regards to the
appointment of Shaun Edward Chilton, aged 57, in accordance with Rule 17 and
Schedule 2(g) of the AIM Rules for Companies:

 

 Current directorships/partnerships:  Former directorships/partnerships (within the last five years):
 Avacta Group plc                     C7 Health Limited
 Bellbrook Consulting Limited         Clinigen Clinical Trials Limited
 Mustang Bidco Limited                Clinigen Consulting Limited
 Mustang Midco Limited                Clinigen CTS Limited
 Mustang Topco Limited                Clinigen Gap Limited
                                      Clinigen Healthcare Limited
                                      Clinigen Holdings Limited
                                      Clinigen International Holdings Limited
                                      Clinigen Limited
                                      Clinigen Pharma Limited
                                      Definigen Limited
                                      IDIS GA Limited
                                      IDIS Group Holdings Limited
                                      IDIS Group Limited

                                      IDIS Limited
                                      IDIS MA Limited
                                      IDIS Pharma Limited
                                      Iovance Biotherapeutics UK SP Ltd
                                      Keats Healthcare Limited

 

Shaun does not hold any shares or options in the Company.

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of
the AIM Rules for Companies.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Alice Woodings                   +44 (0)7980 541 893 / +44 (0)7407 804 654

 Lianne Applegarth                               +44 (0)7584 391 303

 

 

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (Ticker: HVO) is full-service Contract Research
Organisation (CRO) and the global leader in human challenge trials. The
Company delivers end-to-end clinical development services to a diverse and
expanding client base, including seven of the world's ten largest biopharma
companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The Company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/) brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development Consulting
and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp (https://flucamp.com/) . Additionally, its five clinical sites support
outpatient Phase II and III trials, ensuring a seamless and efficient pathway
from discovery to late-stage development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASDLFWFEISESA